Daniel D. Shoemaker
2016
In 2016, Daniel D. Shoemaker earned a total compensation of $713.2K as Chief Scientific Officer at Fate Therapeutics, a 25% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $77,350 |
|---|---|
| Option Awards | $295,800 |
| Salary | $340,000 |
| Total | $713,150 |
Shoemaker received $340K in salary, accounting for 48% of the total pay in 2016.
Shoemaker also received $77.4K in non-equity incentive plan and $295.8K in option awards.
Rankings
In 2016, Daniel D. Shoemaker's compensation ranked 9,798th out of 14,075 executives tracked by ExecPay. In other words, Shoemaker earned more than 30.4% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 9,798 out of 14,075 | 30th |
Division Manufacturing | 3,786 out of 5,486 | 31st |
Major group Chemicals And Allied Products | 1,321 out of 1,900 | 31st |
Industry group Drugs | 1,050 out of 1,543 | 32nd |
Industry Biological Products, Except Diagnostic Substances | 186 out of 287 | 35th |
Source: SEC filing on March 22, 2017.
Shoemaker's colleagues
We found two more compensation records of executives who worked with Daniel D. Shoemaker at Fate Therapeutics in 2016.